Navigation Links
InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
Date:10/29/2013

quires no change in current physician practice – an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) our limited manufacturing capabilities and
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
2. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
3. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
4. Kimberly-Clark Health Care Receives FDA Clearance For KIMGUARD ONE-STEP Sterilization Wrap Portfolio With One-Year Maintenance Of Package Integrity And Amsco V-PRO maX (Flexible Cycle)
5. MiStent SES demuestra ser único en el entorno clínico
6. MiStent SES erweist sich im klinischen Umfeld als einzigartig
7. Pediatric Group Offers Consistent Vision Care Across Its Network with Spot Vision Screener
8. MiStent SES Shown to be Unique in Clinical Setting
9. Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
10. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
11. Freudenberg-NOK Sealing Technologies Announces Screw Connections Based on Hygienic Design Consistently Achievable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... segment of the $13 billion global cardiac rhythm ... Kalorama Information.  Kalorama found that Medtronic, St. Jude ... Medical) command 80% of this market segment. The ... Management Device Markets , uses 2015 as a ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/3rthk2/latest ) ... Regulations on Pharmaceutical International Multi-Center Clinical Trials in ... This is first time in history, Chinese pharmaceutical ... clinical trials of drugs in China ... on March 1, 2015. The guidance provides an ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... , , NEW YORK , ... Jay Hoffman , PhD, professor and chair of the Department of ... , has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and ... in the Journal of the International Society of Sports Nutrition ...
... , SEATTLE , Feb. 11 ... today announced record 2009 sales results. The successful launch of ... in excess of 75% and the company,s first cash flow ... the company,s manufacturing capacity for 2009 and well into 2010. ...
Cached Medicine Technology:Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity 2Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity 3Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity 4Amnis Announces Record 2009 Sales 2
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... Beach, CA (PRWEB) May 23, 2015 Dr. ... Beach, California, has just posted a new article ... gauge repair. As Dr Benvenuti explained in the ... wear enlarged plugs in their earlobes. , Known as “gauging,” ... the earlobe hole, which Dr. Benvenuti said will eventually stretch ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
(Date:5/23/2015)... May 23, 2015 Injury lawyer Steven H. ... been passed by the Maryland legislature but which has not ... General Assembly passed HB 449 with overwhelming bipartisan ... not signed it into law. This bill ensures that fracking ... growing that demonstrates the danger of fracking to our water ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Mountain Point Medical ... a ribbon cutting ceremony on Friday, May 29, 2015 at ... to 6 p.m. The new medical center, set to officially ... Triumph Boulevard, Lehi, UT 84043. , “The opening of ... team and the Utah County community,” said Kent Loosle, CEO ...
Breaking Medicine News(10 mins):Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2
... obese may just have a succor to turn to for ... injections of the gut hormone oxyntomodulin may assist// the obese ... the body, among other hormones that monitor the feelings of ... at Imperial College London observed 15 healthy, overweight men and ...
... Health Service in charge of the North Coast Area has ... on duty//. ,After a patient caused the death of ... to several other patients at Kempsey hospital, the state government ... hospitals. Yet, the nurses’ association is not satisfied with the ...
... for radiation has fallen, wait times for chemotherapy are staying ... a study released by the provincial agency that co-ordinates treatment. ... quality index launched last year showed a drop in the ... seven weeks in 2002. ,However chemotherapy wait times ...
... representative of the World Health Organization (WHO) to Angola ... cholera, which is continuing to sweep// over some Angolan ... having been reported as on April 25. ... this cholera epidemic in Angola has become a national ...
... to a study conducted by Dr. Martina Stippler it was ... outcome of brain injury//. A team at the University Of ... in 83 patients with severe brain injuries. The study results ... of Neurological Surgeons in San Francisco. ,The results ...
... common form of dementia in Canada, affecting some 5% of ... in four people// over the age of 85 suffer from ... St George-Hyslop who is a researcher working on Alzheimer's disease ... single chemical in the brain is the cause of the ...
Cached Medicine News:Health News:Hormone - A Shot in the Arm for Weight Loss 2Health News:Chemotherapy Queues in Ontario Stay Steady 2Health News:Epidemic Of Cholera Continues To Sweep Over Angola 2
Inquire...
Specifically for placing follicular units....
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... Designed as an interactive data-gathering extension ... Advanced Holter runs on your Windows-based PC ... of use in comparative diagnosis. Now you ... into your Workstation with the simple click ...
Medicine Products: